Novo Nordisk A/S (NONOF)
| Previous close | 124.02 |
| Open | 123.45 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 122.20 - 125.01 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 42,204 |
| Market cap | 553.431B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.26 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.50%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by t
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 15 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i
- GlobeNewswire
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets
